In a groundbreaking advancement for infectious disease diagnostics, researchers have successfully developed and validated a highly accurate antibody test for Mpox during the recent clade 1b outbreak in Rwanda. This marks the first instance where an assay of this nature has been clinically validated within the East African context, addressing a critical gap in regional diagnostic capabilities. The novel test, an IgG ELISA (enzyme-linked immunosorbent assay), is capable of detecting immune responses triggered either by natural Mpox infection or vaccination, providing a crucial tool for public health surveillance and outbreak management.
The collaborative effort between the University of Birmingham, Rwanda Biomedical Centre (RBC), and the University of Rwanda underscores an exemplary model of international scientific partnership. The test formation involved meticulous design, optimizing for specificity and sensitivity within a real-world outbreak setting characterized by scarce resources. Leveraging samples obtained from known groups—vaccinated individuals, previously infected patients, and unexposed controls—the research team conducted rigorous validation. This ensured the assay could reliably distinguish between those harboring Mpox antibodies, thereby confirming either past infection or vaccine-induced immunity.
From a technical perspective, the ELISA assay capitalizes on a refined selection of four key antibody signatures targeted against specific Mpox viral proteins. This minimalistic biomarker approach was intentional to keep both the production costs and operational requirements manageable, particularly for laboratories in remote and resource-limited settings. The assay’s design facilitates the use of dried blood spot (DBS) samples, circumventing the need for traditional venipuncture and complex cold chain logistics. This innovation dramatically extends the assay’s applicability in rural clinics and outreach public health programs, catalyzing widespread immunological surveillance in regions vulnerable to Mpox spread.
By quantifying the presence of IgG antibodies, the assay enables health authorities to map infection chains more precisely, identify at-risk groups needing prioritized vaccination, and comprehend the dynamics of population immunity over time. These factors are instrumental in crafting responsive and data-driven outbreak containment strategies. Furthermore, the antibody test enhances the capacity for epidemiological studies aiming to unravel Mpox viral transmission networks, a subject historically hampered by the absence of reliable serological tools in Africa.
The MpoxCARE project, within which this assay was developed, highlights the critical intersection of scientific innovation and capacity building. Beyond the assay’s immediate clinical utility, the project embodies a commitment to strengthening local biomedical infrastructure and expertise in Rwanda. Training programs for laboratory technicians, integration of research competencies at the National Reference Laboratory in Kigali, and the fostering of cross-institutional collaborations have jointly contributed to establishing a sustainable scientific ecosystem adept at confronting current and future epidemic threats.
Prof. Christopher Green of the University of Birmingham, a lead investigator on the MpoxCARE study, emphasized the transformative nature of conducting “high-quality research in equal partnership with talented scientists in Rwanda in a time of need.” Such collaborations are pivotal in moving away from traditional paradigms of external interventions toward co-created scientific solutions that are contextually relevant and immediately actionable. This test stands as a real-world manifestation of research translating directly into enhanced global health security.
The longstanding partnership between the UK-based University of Birmingham and Rwanda Biomedical Centre exemplifies how sustained engagement and mutual capacity development can yield practical health tools. This relationship facilitates rapid translational research tailored to emergent outbreaks of vaccine-preventable diseases and underscores the benefits of integrating NHS and NIHR infectious disease expertise with African public health mandates. The Mpox antibody ELISA is a testament to this synergy, bridging cutting-edge biomedical research with public health imperatives in East Africa.
Equally significant is the assay’s validation on locally collected blood samples, reinforcing its accuracy and applicability to the genetic diversity of the East African population’s immune responses. This context-specific validation guarantees the test’s fitness for purpose, overcoming the limitations posed by generic assays developed and calibrated in non-endemic regions. The ability to employ DBS samples further enhances test deployment where phlebotomy resources are scarce, democratizing access to advanced serological diagnostics.
Professor Claude Mambo Muvunyi, Director General of RBC, acknowledged the assay’s role in advancing Rwanda’s leadership in epidemic research and surveillance. The strengthened National Reference Laboratory capacity to validate novel diagnostics positions Rwanda as a regional hub for epidemic preparedness, not only for Mpox but for a broader spectrum of emerging infectious diseases. This advancement is critical in empowering African nations to lead surveillance efforts and tailor public health responses grounded in robust scientific evidence.
Moreover, Professor Alex Richter from the University of Birmingham highlighted the importance of cross-sectoral and international collaboration, recognizing that “working collaboratively across sectors and across countries has enabled the rapid development of our test.” This collective approach ensured the assay was custom-built for the Rwandan context, maximizing its relevance and impact. Such models of partnership represent a forward-looking blueprint for tackling other infectious diseases in sub-Saharan Africa and beyond.
This achievement comes amid growing global concern about Mpox outbreaks and reemergence potentials, especially in regions with limited diagnostic infrastructures. The assay equips health authorities with a critical investigative tool that, alongside vaccination efforts, strengthens the interdisciplinary framework necessary for effective viral containment. Beyond Mpox, the methodological advancements demonstrated by this ELISA platform promise utility in other zoonotic and outbreak-prone pathogens, signaling a broad horizon in infectious disease diagnostics.
In sum, the successful development and validation of this Mpox antibody test embody a fusion of scientific rigor, strategic collaboration, and public health pragmatism. Its deployment offers a tangible leap forward in controlling Mpox transmission, illuminating infection dynamics, and tailoring vaccination strategies in East Africa. As infectious disease threats evolve in complexity, the model created by the MpoxCARE project charts a resilient pathway rooted in equitable partnerships, accessible technologies, and localized research leadership.
Subject of Research: People
Article Title: A combined ELISA for infection-induced and vaccine-induced mpox antibodies during the clade Ib outbreak in Rwanda: an observational, cross-sectional, clinical validation study
News Publication Date: 9-Mar-2026
Web References: http://dx.doi.org/10.1016/S1473-3099(26)00006-X
References: The Lancet Infectious Diseases
Keywords: Infectious diseases, Immunology, Immunoassays
Tags: East Africa infectious disease diagnosticsMpox antibody test validationMpox clinical assay developmentMpox diagnostic specificity and sensitivityMpox IgG ELISA assayMpox immune response detectionMpox outbreak RwandaMpox public health surveillance toolsMpox vaccination antibody detectionMpox viral protein biomarkersRwanda Biomedical Centre researchUniversity of Birmingham Mpox study
